Nyhet -

Maximising Drug Discovery Research- Interview with Attana CEO, Teodor Aastrup

"Drug discovery scientists should focus on the biological relevance of their candidate molecules as soon as possible in their research, to ensure a high probability of success in later stages”, says Teodor Aastrup, Chief Executive Officer and Founder of Attana AB. To maximise productivity, there is a need to understand reactions and interactions in the human body before research has advanced too much."

Click here to read the entire interview or access the pdf attached below.

Relaterade länkar

Ämnen

  • Vetenskap, teknik

Kategorier

  • discovery summit 2011
  • biosensor
  • attana cell 200
  • marcus evans
  • attana
  • drug discovery

Kontakter

Relaterat innehåll

  • Characterisation of complex lectin-cell kinetics (Attana Application Example)

    Attana Cell 200 - Label free, real time kinetics on cells, exploring biology on a new level!
     
    In the development process of new pharmaceutical compounds, kinetic experiments provide insights
    into potential drug candidates while also defining lead targets. In this application example we demonstrate the ability of the Attana Cell™ 200 to provide a complete and highly relevant analysis of a

  • Fight against cancer - Attana's collaborator interviewed

    Attana's collaborator at Gothenburg University, Dr. Sture Lindegren, is interviewed about a possible new cure for ovarian cancers. Using the Attana Cell 200 instrument, Dr. Lindegren and his team are testing antibodies as carriers of radionuclide that target cancer cells directly instead of affecting the whole body as current cancer therapies do.

Relaterade event